Restrictive Coverage Policies and Patient Access

Please read this timely article by Mark Ballow, M.D. published in Healthcare Payer News. Dr. Ballow addresses restrictive coverage policies that have a negative impact on patient access and patient care; particularly focusing on patients with primary immunodeficiency diseases.

PPTA News

PPTA Statement on FDA Guidance Documents +

PPTA is aware of the guidance documents released by the U.S. Food and Drug Administration on April 2 regarding Source plasma donor eligibility and is currently evaluating them. Our focus remains, as it has for nearly three decades, on patient and donor safety, and the safety of therapies derived from plasma.
Read More
PPTA Responds to The Guardian Article +

An article published March 25 by Stefanie Dodt and Samuel Gilbert in The Guardian continues the authors’ intentional maligning of plasma donors along the U.S.-Mexico border and perpetuates a divisive misrepresentation of the reality of border life between the United States and Mexico. The Plasma Protein Therapeutics Association (PPTA) and its member companies are grateful for every plasma donor, each of whom directly contributes to saving and improving the lives of people facing serious, inherited, and life-threatening diseases.
Read More
Letter to CMS to Allow Home Infusion COVID +

Dear Administrator Verma,

I am writing to ask for your consideration as the Centers for Medicare and Medicaid Services explores avenues to protect vulnerable patient populations during the COVID-19 pandemic. The Plasma Protein Therapeutics Association (PPTA) is the standard setting and global advocacy organization that represents plasma donation centers and manufacturers of plasma protein therapies. Our membership accounts for approximately 80% of plasma therapies in the United States. These therapies treat individuals with rare, chronic, and life-threatening conditions, such as immune deficiencies, certain neurological diseases, alpha-1 antitrypsin deficiency, and bleeding disorders.
Read More
New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies +

The 2019 Novel Coronavirus (2019-noCoV), now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified by Chinese authorities in December 2019 in Wuhan province, China (1, 2). Infection with the virus is in most cases associated with an illness known as ‘COVID-19’, an abbreviation for ‘coronavirus disease 2019’ (3, 4).
Read More

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Restrictive Coverage Policies and Patient Access

PPTA Statement on FDA Guidance Documents +

PPTA Responds to The Guardian Article +

Letter to CMS to Allow Home Infusion COVID +

New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies +

Media and Information

Advocacy